Loading…
Employees: 1,181
Size Zhong Zhu Healthcare (600568.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $628M, the 3318th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥2.10 on 6 Nov 2026.
Performance Over six months the shares fell 21.1%, against -20.8% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue fell 5.5% over the last twelve months (peer median +2.2%); the operating margin is -33.8% (peer median 5.0%).
Valuation It trades at 7.1× enterprise value to sales against a peer median of 2.9× (5th most expensive of 18).
Capital Return on invested capital runs 14.1 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥536M | CN¥576M | CN¥520M | CN¥636M | CN¥504M |
| Revenue growth | — | +11% | -18% | +26% | — |
| Gross profit | CN¥85.4M | CN¥74.3M | CN¥36.0M | CN¥107M | CN¥66.7M |
| EBITDA | n/a | -CN¥66.4M | -CN¥208M | -CN¥45.1M | -CN¥139M |
| Net income | -CN¥153M | -CN¥114M | -CN¥620M | -CN¥344M | -CN¥799M |
| Free cash flow | -CN¥4.50M | CN¥32.4M | CN¥24.9M | -CN¥23.7M | CN¥913,940 |
| Capital expenditure | CN¥20.6M | CN¥32.1M | CN¥12.8M | CN¥27.3M | CN¥26.0M |
| Total debt | CN¥44.5M | CN¥23.5M | CN¥16.4M | CN¥23.9M | CN¥275M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600568.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.9% | -6.6% | 10th lowest of 21 |
| 6-month return | -21.1% | -20.8% | 10th lowest of 21 |
| Distance from 52-week high | -35.8% | -36.2% | 9th highest of 21 |
| Revenue growth (TTM) | -5.5% | +2.2% | 6th lowest of 18 |
| Operating margin | -33.8% | 5.0% | 5th lowest of 18 |
| EV / Sales | 7.1× | 2.9× | 5th most expensive of 18 |
| ROIC minus cost of capital | -14.1 pp | -1.5 pp | 4th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhong Zhu Healthcare 600568.SS | China | $628M | -21% | -6% | -34% | 7.1× | n/a | n/a |
| DBV Technologies DBV.PA | France | $633M | -47% | n/a | n/a | n/a | n/a | n/a |
| Innova Captab INNOVACAP.NS | India | $618M | +18% | +34% | 12% | 3.3× | 25.4% | +31.4% |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $638M | -12% | -2% | 8% | 1.0× | -4.9% | +6.5% |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $617M | -22% | -21% | 32% | 2.2× | -14.3% | +2.8% |
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | n/a | n/a | n/a | n/a |
| Chongkundang 185750.KS | South Korea | $611M | -26% | +7% | 4% | 0.5× | n/a | n/a |
| Aclaris Therapeutics ACRS | United States | $604M | -21% | -51% | -1,040% | 62.6× | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $652M | -21% | +37% | -510% | 107.7× | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $653M | -11% | -3% | -1% | 2.5× | 12.1% | -5.9% |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $657M | -4% | -6% | 5% | 2.9× | 23.2% | +21.9% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $598M | -23% | -3% | 7% | 1.4× | -3.2% | +4.1% |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $661M | -25% | +2% | 4% | 1.4× | 1.1% | -1.6% |
| TTY Biopharm 4105.TWO | Taiwan | $596M | +7% | +5% | 33% | 2.9× | -11.1% | +8.8% |
| Lepu Biopharma 2157.HK | Hong Kong | $663M | -45% | +47% | 7% | 5.1× | n/a | n/a |
| Supriya Lifescience SUPRIYA.NS | India | $593M | -1% | +28% | 30% | 6.4× | 27.9% | +15.8% |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $664M | -26% | -10% | -9% | 2.2× | 0.3% | -17.9% |
| Sun Pharma Advanced Research SPARC.NS | India | $665M | +16% | +3,141% | 84% | 2.6× | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -65% | 19.0× | n/a | n/a |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | n/a | n/a | n/a | n/a |
| Abbisko Cayman 2256.HK | Hong Kong | $589M | -48% | -83% | -520% | 20.8× | n/a | n/a |